Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Early Phase 1
2(50.0%)
4Total
Phase 2(2)
Early Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06888102Early Phase 1Recruiting

A Platform Study of Epigenetic Therapy Before Prostatectomy in Men With Prostate Cancer

Role: lead

NCT05534646Phase 2Recruiting

Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer

Role: lead

NCT05567679Early Phase 1Withdrawn

A Study of Tazemetostat (Tazverik) Before Prostatectomy in Men With Prostate Cancer

Role: lead

NCT01834651Phase 2Completed

A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases

Role: lead

All 4 trials loaded